Biohaven Ltd. (BVMF:BHVN34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 9.83B +107.9% |
| Revenue (ttm) | n/a |
| Net Income | -2.81B |
| EPS | -6.99 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 23.13 |
| Previous Close | 23.13 |
| Day's Range | 23.13 - 23.13 |
| 52-Week Range | 13.90 - 28.29 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About Biohaven
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim... [Read more]
News
Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting
Biohaven presents three posters at ATA, highlighting the patient experience, autoimmune biology of disease, and MoDE and TRAP platform, reflecting a research program built around a condition that rema...
Biohaven price target raised to $21 from $19 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Biohaven (BHVN) to $21 from $19 and keeps an Overweight rating on the shares.
Biohaven price target raised to $32 from $21 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Biohaven (BHVN) to $32 from $21 and keeps a Buy rating on the shares. The firm updated its model followng…
Biohaven reports Q3 adjusted EPS (73c) vs. ($1.47) last year
Cash, cash equivalents, marketable securities and restricted cash as of September 30, 2026, totaled approximately $164.0 million. On October 20, 2026, Biohaven (BHVN) received $80.0 million from Ono P...
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
The US Food and Drug Administration (FDA) accepted new drug application resubmission for Vyglxia (troriluzole) in spinocerebeller ataxia (SCA), user fee goal date 1Q27. Announced exclusive global lice...
Biohaven Quarterly report: Q3 2026
Biohaven has published its Q3 2026 quarterly earnings report on October 29, 2026.
Biohaven Earnings release: Q3 2026
Biohaven released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Biohaven presents preclinical data for novel TRAP degrader at ASN Kidney Week
Biohaven (BHVN) presented preclinical data for BHV-1420 in an oral presentation at the American Society of Nephrology, or ASN, Kidney Week 2026 in Denver, Colorado. BHV-1420 is a novel TRAP…
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
One year after Biohaven's first TRAP degrader, BHV-1400, was highlighted in the Kidney Week opening plenary, Biohaven's second TRAP degrader for kidney disease expands its Yale-licensed platform into ...
Biohaven price target raised to $22 from $19 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on Biohaven (BHVN) to $22 from $19 and keeps a Sector Perform rating on the shares. The firm updates its…
Biohaven price target raised to $48 from $42 at Baird
Baird raised the firm’s price target on Biohaven (BHVN) to $48 from $42 and keeps an Outperform rating on the shares. The firm updated its model following results which showed…
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven's experimental spinocerebellar ataxia treatment.
Why Is Biohaven Stock (BHVN) Up 34% Today?
Biohaven stock rallied over 34% on Thursday following an update from the FDA on the company’s treatment for SCA.
Biohaven shares jump 29% premarket as FDA accepts Vyglxia resubmission
In a regulatory filing, Biohaven (BHVN) announced that the FDA has informed Biohaven that the company’s new drug application resubmission for Vyglxia in SCA has been accepted for review. The…
Biohaven enters strategic licensing, collaboration pact with Ono Pharmaceutical
Biohaven (BHVN) announced that it has entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical, under which Ono will obtain an exclusive license to develop and commercial...
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-g...
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeuti...
Citi views Xenon study pause as positive for Biohaven
Citi analyst Samantha Semenkow views Xenon Pharmaceuticals’ (XENE) voluntarily pause in new enrollment for its ongoing trials for major depressive disorder and bipolar depression as favorable for Bioh...
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trials NEW YORK, Sept...
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
Biohaven clinical hold adds level of uncertainty, says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao keeps a Neutral rating on Biohaven (BHVN) with a $10 price target after the FDA issued a partial clinical hold, pausing new patient enrollment across…
Impact of Biohaven’s partial FDA hold ‘manageable,’ says Raymond James
Biohaven’s (BHVN) partial FDA hold on new enrollment for BHV-7000 has driven a 15% selloff, but the setback appears manageable given SK Bio’s prior awareness and continued commitment to its…
Biohaven down 15% after FDA puts partial clinical hold on BHV-7000 program
In a regulatory filing earlier, Biohaven (BHVN) provided updates to the BHV-7000 program. The company stated: In January 2024, we completed our End-of-Phase 2 meeting with the U.S. Food and…